CLYM Climb Bio, Inc. stock chart & analysis

Conviction 36HealthcareScan · Fri, Nov 6, 2026

Morning star

Climb Bio, Inc. (CLYM) closed at $10.29 (+16.01%) on Nov 6, 2026. Its latest daily candle is a morning star. Price is below its 50-day and below its 200-day moving average. RSI(14) 48, RS Rating 99, -43.8% from its 52-week high, +157.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.

CLYM$10.29+16.01%

ResistanceSupportVol 14Insider sell

Loading chart…

Climb Bio, Inc.Pharmaceutical Preparationswww.climbbio.com ↗

Price10.29

Change+16.01%

Gap+2.25%

Rel volume1.88×

Avg volume1.27M

Avg $ vol12.49M

SMA 2010.07

SMA 5011.91

SMA 20010.51

Price vs 50-13.42%

Price vs 200-1.93%

MA stackmixed

50/200 cross—

Supertrenddown · 11.23

RSI (14)48

MACD hist0.09

MACD cross—

Stoch %K / %D66 / 35

ADX (14)39

+DI / −DI18 / 28

RSI divergence—

MACD divergenceBullish

ATR %8.33%

ADR %8.17%

52w high18.33

52w low1.64

From 52w high-43.75%

Above 52w low+530.58%

New 52w highNo

SqueezeOff

Bollinger width23.79%

%B0.60

Donchian pos65.88%

Donchian high11.26

Donchian low8.49

AVWAP (52w high)12.47

vs AVWAP high-17.31%

AVWAP (52w low)9.76

vs AVWAP low+5.68%

OBV trendFlat

Chaikin MF (20)-0.14

Today vs 20d1.88×

Avg vol (14d)1.42M

Avg vol (20d)1.27M

Avg $ vol (20d)12.49M

Market cap605.59M

RS Rating99 / 99

RS 3m (vs SPY)-18.99%

RS 6m (vs SPY)-9.02%

RS line new highNo

Trend template3/8

Technical rank45.3

1 week+0.59%

1 month-5.06%

3 months-23.86%

6 months-9.32%

1 year+436.98%

YTD+157.75%

P/E-10.12

P/B2.66

P/S—

P/FCF-11.10

EPS-0.8800

Div yield—

ROE-26.24%

ROA-25.30%

Debt/Eq—

Current26.58

EV/EBITDA-8.35

Gross margin—

Net margin—

Rev growth—

EPS growth19.01%

Price target29.09

Target upside182.15%

Analyst ratingBuy

Institutional102.97%

Ent. value565.86M

Revenue—

Net income-14.57M

Gross profit—

Free cash flow-54.54M

IndustryPharmaceutical Preparations

ExchangeNasdaq

Shares out57.26M

Employees29

ListedTue, Aug 10, 2021

Free float19.95M

Float %41.8%

Short interest—

Days to cover—

Short volume61.1%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est−$0.18 vs −$0.20

Last surprise+10.0% beat

Setup gradeD

Conviction36 / 100

Pattern quality—

Tech rank45.3 / 100

Group rank23 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmMorning star

Financials as of Wed, Sep 30, 2026 · quarterly.

CLYM technical analysis

Trend

CLYM's moving averages are mixed — no clean uptrend or downtrend. It closed 13.4% below the 50-day ($11.91) and 1.9% below the 200-day ($10.51). ADX(14) at 39 points to a strong, established trend. It meets 3 of 8 trend-template criteria.

Momentum

RSI(14) is 48, in the bearish half of its range. The MACD histogram is positive. A bullish MACD divergence is in place. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.

Volume and volatility

Volume on the latest session ran 1.9× its 20-day average. It trades about $12.5M a day on average. ATR(14) is $0.8589, 8.3% of price — its typical daily range. Chaikin Money Flow (-0.14) shows distribution.

Key levels

The 52-week range is $1.64 to $18.33; price is 43.8% below the high and 530.6% above the low. The VWAP anchored at the 52-week high is $12.47, above price.

Performance

CLYM returned +0.6% (1 week), -5.1% (1 month), -23.9% (3 months), -9.3% (6 months), +437.0% (1 year), +157.8% (year to date).

About Climb Bio, Inc.

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Pharmaceutical Preparations · Listed 2021 · 29 employees

Insider activity

SEC Form 4 transactions in CLYM · open-market 2 sells

Insider	Side	Shares	Value	Traded	Filed
Thomas Stephen Basil Director · Common Stock · 2026-09-15	Sell	100K	$1.4M	2026-09-15	2026-09-17
Brennan Aoife President and CEO · Common Stock · 2026-06-29	Sell	30.9K	$407K	2026-06-29	2026-06-30
Brennan Aoife President and CEO · Restricted Stock Units · 2026-06-27	Exercise	68.75K	—	2026-06-27	2026-06-30
Brennan Aoife President and CEO · Common Stock · 2026-06-27	Exercise	68.75K	—	2026-06-27	2026-06-30
Drapkin Kimberlee C Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
WILLIAMS DOUGLAS E Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
Thomas Stephen Basil Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
RA CAPITAL MANAGEMENT, L.P. Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
RA Capital Nexus Fund II, L.P. Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08
RA Capital Nexus Fund, L.P. Director · Stock Option (Right to Buy) · 2026-06-05	Grant	40K	$0	2026-06-05	2026-06-08

SEC filings

EDGAR filings in CLYM · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.